PMC:7530350 / 150-327 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T3","span":{"begin":41,"end":49},"obj":"Body_part"},{"id":"T4","span":{"begin":71,"end":84},"obj":"Body_part"}],"attributes":[{"id":"A3","pred":"fma_id","subj":"T3","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A4","pred":"fma_id","subj":"T4","obj":"http://purl.org/sig/ont/fma/fma264829"}],"text":"Treatment with tocilizumab, a monoclonal antibody directed against the interleukin-6 (IL-6) receptor, was shown to lead to clinical improvement in patients with severe COVID-19."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T4","span":{"begin":168,"end":176},"obj":"Disease"}],"attributes":[{"id":"A4","pred":"mondo_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Treatment with tocilizumab, a monoclonal antibody directed against the interleukin-6 (IL-6) receptor, was shown to lead to clinical improvement in patients with severe COVID-19."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T3","span":{"begin":28,"end":29},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T4","span":{"begin":71,"end":84},"obj":"http://purl.obolibrary.org/obo/PR_000001393"}],"text":"Treatment with tocilizumab, a monoclonal antibody directed against the interleukin-6 (IL-6) receptor, was shown to lead to clinical improvement in patients with severe COVID-19."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T1","span":{"begin":15,"end":26},"obj":"Chemical"},{"id":"T2","span":{"begin":86,"end":88},"obj":"Chemical"}],"attributes":[{"id":"A1","pred":"chebi_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A2","pred":"chebi_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A3","pred":"chebi_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"}],"text":"Treatment with tocilizumab, a monoclonal antibody directed against the interleukin-6 (IL-6) receptor, was shown to lead to clinical improvement in patients with severe COVID-19."}

{"project":"LitCovid-PubTator","denotations":[{"id":"13","span":{"begin":71,"end":84},"obj":"Gene"},{"id":"15","span":{"begin":147,"end":155},"obj":"Species"},{"id":"17","span":{"begin":15,"end":26},"obj":"Chemical"},{"id":"20","span":{"begin":168,"end":176},"obj":"Disease"}],"attributes":[{"id":"A13","pred":"tao:has_database_id","subj":"13","obj":"Gene:3569"},{"id":"A15","pred":"tao:has_database_id","subj":"15","obj":"Tax:9606"},{"id":"A17","pred":"tao:has_database_id","subj":"17","obj":"MESH:C502936"},{"id":"A20","pred":"tao:has_database_id","subj":"20","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Treatment with tocilizumab, a monoclonal antibody directed against the interleukin-6 (IL-6) receptor, was shown to lead to clinical improvement in patients with severe COVID-19."}

{"project":"LitCovid-sentences","denotations":[{"id":"T5","span":{"begin":0,"end":177},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Treatment with tocilizumab, a monoclonal antibody directed against the interleukin-6 (IL-6) receptor, was shown to lead to clinical improvement in patients with severe COVID-19."}